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The lengthy course of treatment with currently used
antimycobacterial drugsand the resulting emergence
of drug-resistant strains have intensified the need for
alternative therapies against Mycobacterium tuber-
culosis (Mtb), the etiologic agent of tuberculosis. We
show that Mtb and Mycobacterium marinum use
ABL and related tyrosine kinases for entry and intra-
cellular survival in macrophages. In mice, the ABL
family tyrosine kinase inhibitor, imatinib (Gleevec),
when administered prophylactically or therapeuti-
cally, reduced both the number of granulomatous
lesions and bacterial load in infected organs and
was also effective against a rifampicin-resistant
strain. Further, when coadministered with current
first-line drugs, rifampicin or rifabutin, imatinib acted
synergistically. These data implicate host tyrosine
kinases in entry and intracellular survival ofmycobac-
teria and suggest that imatinib may have therapeutic
efficacy againstMtb. Because imatinib targets host, it
is less likely to engender resistance compared to
conventional antibiotics andmaydecrease the devel-
opment of resistance against coadministered drugs.
INTRODUCTION
Mycobacterium tuberculosis (Mtb), the etiologic agent of tuber-
culosis (TB), infects one-third of the world’s population and kills
approximately 2 million people per year worldwide (WHO, 2000),
with a global case fatality rate of 23% (Bleed et al., 2000). Esti-
mates indicate that more than 90% of all cases of TB and 98%
of deaths due to TB occur in developing countries in Southeast
Asia, the Western Pacific, and Africa (Raviglione et al., 1995;
Snider and La Montagne, 1994). In 1993, the magnitude andCell Host &potential impact of this pandemic prompted the World Health
Organization to declare TB a global health emergency. It is esti-
mated that over the next two decades nearly one billion people
will become infected, 200 million people will develop disease,
and 35 million people will die from TB (WHO, 2000).
Although highly effective regimens have been developed
for the treatment of TB patients, drugs must be administered
for a minimum of six months to cure the disease. Nonadherence
with the lengthy course of treatment remains a major problem
and has contributed to the emergence of multidrug-resistant
(MDR) and extensively drug-resistant(XDR) TB strains, which
complicates the treatment and control of TB and threatens to
exacerbate the epidemic (Dye et al., 2002; Farmer and Kim,
1998). Availability and quality of drugs and altered pharmacoki-
netics of absorption of some drugs in persons with AIDS has
also contributed to the development of drug resistance (Cantwell
et al., 1994). Thus, new anti-TB drugs are urgently needed to
combat drug resistance, shorten and/or simplify current treat-
ment regimens, provide effective therapy for patients intolerant
to current first-line drugs, and provide treatment for patients
with latent TB infection.
A key featureofMtbpathogenesis is theability of thebacteria to
survive and replicate in host phagocytic cells (Russell et al., 2002).
Mtb can use asmany as eight different cell surface receptors, and
it appears to enter macrophages through conventional phagocy-
tosis (Ernst, 1998). Upon infection, mycobacteria reside within
a specialized early phagosomal compartment. Pathogenicmyco-
bacteria prevent fusion with the lysosome, which facilitates
evasion of host bactericidal mechanisms and precludes efficient
antigen presentation (Russell et al., 2002). Although there is a
wealth of information onMtb factors that contribute to entry and
intracellular survival within macrophages, information on host
factors that contribute to these processes remains more limited.
We have been studying mechanisms by which host tyrosine
kinases (TKs) and, in particular, the ABL family TKs, ABL1 and
ABL2, mediate pathogenesis of bacteria and viruses (Lebeis and
Kalman, 2009). ABL1 is mutated in human cancers such as
chronic myelogenous leukemia (CML). Drugs such as imatinibMicrobe 10, 475–485, November 17, 2011 ª2011 Elsevier Inc. 475
Figure 1. SRC and ABL Family TKIs Reduce
Intracellular Survival of Mycobacterium
tuberculosis and Mycobacterium marinum
In Vitro
(A and B) Intracellular survival ofMtbH37Rv (moi =
10) in J774A.1 macrophage-like cells treated with
PD-166326 (10 mM), an SRC and ABL family TKI,
the carrier DMSO (0.1%; control) (A), or imatinib
(10 mM), an ABL family TKI (B).
(C) Effects of PD-166326 or imatinib (each at
10 mM) onMtbH37Rv in THP-1 cells, J774A.1 cells
left untreated or treated with IFNg, or A549 cells.
Ordinate represents maximal fold reduction at
8 days p.i. with respect to DMSO controls.
(D) Intracellular survival of Mm 1218R (moi = 1) in
J774A.1 cells treated with imatinib (10 mM).
(E and F) Growth curves of Mtb H37Rv (E) or Mm
1218R (F) in 7H9 broth containing PD-166326
(10 mM), imatinib (10 mM), or DMSO (0.1%). OD600
was measured at times indicated. Data points
represent the mean of three separate experi-
ments, and error bars are +/ SEM.
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related TKs, are used as therapeutics for CML and other cancers
(Druker et al., 2001). Pseudomonas aeruginosa, Shigella flexneri,
and Chlamydia trachomatis (Burton et al., 2003; Elwell et al.,
2008; Pielage et al., 2008) utilize ABL family TKs during entry,
although the precise mechanisms remain unclear. ABL family
TKs also regulate cytoskeletal and trafficking functions in cells,
including autophagy (Yogalingam and Pendergast, 2008). In this
regard, Shigella flexneri, enteropathogenic Escherichia coli, and
orthopoxviruses utilize ABL family TKs for actin-based motility or
release from infected cells, which facilitate spread of the infection
(Burtonet al., 2005;Reeveset al., 2005,2011;Swimmetal., 2004).
The requirement for ABL family TKs in the pathogenesis of
diverse microbes led us to assess their role in Mtb infection.
Using cell lines lacking ABL family TKs and specific inhibitors,
we show that ABL family and related imatinib-sensitive kinases
facilitate entry and intracellular survival of Mtb and the related
Mycobacterium marinum (Mm). Additionally, imatinib reduces
bacterial load and associated pathology in mice infected with
Mtb and Mm, including antibiotic-resistant strains. Moreover,
imatinib acted in a synergistic manner with the frontline anti-TB476 Cell Host & Microbe 10, 475–485, November 17, 2011 ª2011 Elsevier Inc.drugs, such as rifampicin and rifabutin.
Together, our data suggests that modula-
tion of ABL1, ABL2, and related imatinib-
sensitive kinases may offer an effective
therapeutic strategy for infections caused
by mycobacterium species.
RESULTS
SRC and ABL Family Tyrosine
Kinase Inhibitors Affect
Intracellular Survival of
Mycobacterium tuberculosis and
Mycobacterium marinum In Vitro
J774A.1 cells, a murine macrophage-like
cell line, were infected with Mtb strainH37Rv in media supplemented with PD-166326, an inhibitor of
SRC and ABL family TKs; dimethyl sulfoxide (DMSO), the carrier
for PD-166326 (Figure 1A); or imatinib mesylate (imatinib), an
inhibitor of ABL but not SRC family TKs (Figure 1B). PD-
166326 or imatinib caused a reduction in cfu/ml by up to 2-fold
compared to the carrier at time 0 and up to 7.7-fold at 8 days
postinfection (p.i.) (Figures 1A and 1B). Comparable effects of
tyrosine kinase inhibitors (TKIs) were evident in several cell lines,
including A549 cells, a human type II alveolar pneumocyte cell
line, and THP-1 cells, a human monocyte cell line (Figures 1C
and S1A–S1E available online). Moreover, the effects of TKIs
on J774A.1 cells were independent of stimulation with inter-
feron-g (INF-g) (Figures 1C and S1A).
To determine whether TKIs affected other Mycobacterium
species, we assessed their effects on intracellular survival of
Mm and Mycobacterium smegmatis (Ms) in J774A.1 cells. As
with Mtb, PD-166326 or imatinib decreased cfu/ml by up to
9-fold at both early and late time points for bothMm andMs (Fig-
ure 1D and data not shown). TKIs had no effect on the growth of
Mtb, Mm, or Ms in 7H9 broth supplemented with PD-166326
or imatinib at concentrations as high as 10 mM (e.g., Figures 1E
Figure 2. ABL Family TKs and Other Imati-
nib-Sensitive Kinases Mediate Intracellular
Survival of Mycobacterium tuberculosis
and Mycobacterium marinum
(A) J774A.1macrophageswere infectedwithGFP-
Mm for 2 h in the presence or absence of imatinib
(10 mM), and treated for an additional 2 h with
media supplemented with amikacin to kill extra-
cellular bacteria. The number of infected cells,
measured as those containing GFP-positive
bacilli, was quantified by fluorescence micros-
copy.
(B) THP-1 cells were infected withMtb and treated
with imatinib at concentrations ranging from 0.1 to
10 mM for 2 h. Drug was removed and cells were
incubated for an additional 2 h with amikacin to kill
extracellular bacteria, and then harvested 20 h
later to determine cfu/ml.
(C) J774A.1 macrophages were treated with im-
atinib (10 mM) and incubated with Mm at 4C
before returning the cells to 37C to synchronize
entry. At various times thereafter, drug was
removed and the cells were treated with amikacin
for 2 h. Cells were then lysed and cfu were deter-
mined.
(D) J774A.1 macrophages were infected with Mm
1218R (moi = 1) for 2 h and then incubated with
amikacin for an additional 2 h. After washing,
media was added, with or without 10 mM imatinib.
Cfu/ml was determined at various time points
thereafter.
(E and F) J774A.1 cells were infected and treated
as in (D), stained 24 h p.i. with lysotracker red, and
visualized live. The percent of GFP-Mm colocal-
izing with the lysotracker red-labeled compart-
ment was quantified (250 bacteria from three
experiments). Scale bar represents 5 mM.
(G) Fibroblasts derived from ABL1//ABL2/
mice or from age-matched wild-type mice were
infected with Mm 1218R (moi = 60) for 4 h. Cells
were treated with amikacin for 2 h and cfu/ml was
determined at various time points thereafter.
Imatinib or carrier was present throughout. Data
represent the mean +/ SEM from three
experiments.
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of imatinib-sensitive host TKs reduce the cfu of several Myco-
bacterium species in cells at both early and late time points after
inoculation.
ABL and Other Imatinib-Sensitive Tyrosine Kinases
Mediate Entry and Intracellular Survival ofMycobacteria
in Macrophages
We next determined whether imatinib-sensitive TKs mediate
either entry or intracellular survival of mycobacteria within the
macrophage, or both. To distinguish these possibilities,
J774A.1 cells were inoculated withMm constitutively expressing
green fluorescent protein (GFP) (GFP-Mm) and treated first with
imatinib for 2 h and thenwith amikacin for another 2 h to kill extra-
cellular bacteria. Imatinib caused a 2.9-fold reduction of the
number of GFP-positive cells (Figure 2A). In accordance with
these data, imatinib produced 2-fold reduction in cfu/ml whenCell Host &added to THP-1 cells for only 2 hr at the time of inoculation
with Mtb (Figure 2B). A similar fold reduction was evident when
imatinib was added to J774A.1 cells for only 15 min at the time
of inoculation with Mm (Figure 2C). These data suggest that
imatinib-sensitive kinases mediate the entry of mycobacteria.
To determine whether imatinib had additional effects on intra-
cellular survival independent of entry, J774A.1 cells were in-
fected inmedia only and the drug was added 4 h p.i. for the dura-
tion of the experiment (Figure 2D). Using this protocol, imatinib
reduced cfu/ml by 3.4-fold. To determine whether this reduction
in cfu resulted from increased phagolysosomal fusion, macro-
phages were infected with GFP-Mm, treated with amikacin to
kill extracellular bacteria, and then treated with imatinib for an
additional 24 h. Live macrophages were then stained with lyso-
tracker red, a lysosomal marker. In accordance with previous
reports (Ertmer et al., 2007), imatinib caused an increase in the
area of the lysotracker-labeled compartment, even in uninfectedMicrobe 10, 475–485, November 17, 2011 ª2011 Elsevier Inc. 477
Figure 3. Imatinib Reduces Bacterial Load in Mice
Infected with Mycobacterium marinum
(A) C57Bl/6 mice were injected in the tail vein with 105 cfu
Mm 1218R. Beginning 24 h prior to infection, animals were
administered water (carrier) or imatinib at concentrations
of 25, 50, 66.7, 100, or 200 mg/kg/day. Cfu/g was deter-
mined in spleen at 7 days p.i.
(B and C) Mice were infected with Mm as in (A) and pre-
treated with carrier or with imatinib (100mg/kg/day). Cfu/g
from liver (B) or lungs (C) was determined at 7 days p.i.
(D and E) Mice were infected with Mm as in (A–C), but
administration of imatinib (100 mg/kg/day) commenced
1 h (D) or 24 h (E) p.i. Cumulative data from at least three
experiments are presented. Each point represents an
individual mouse, and the line represents the median cfu;
p values were determined by a nonparametric Mann-
Whitney rank sum test.
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ABL Family Kinases Regulate Mycobacterial Infectioncells (Figure 2E). As shown in Figures 2E and 2F, 5.8-fold more
GFP-Mm was evident in lysotracker-labeled compartments
upon treatment with imatinib compared to untreated cells.
Collectively, these data indicate that an imatinib-sensitive
kinase(s) regulates both entry and phagolysosomal trafficking
of mycobacteria.
ABL Family Tyrosine Kinases and Other Imatinib-
Sensitive Kinases Mediate Intracellular Survival
of Mycobacterium marinum
To determine if ABL1 andABL2 have a direct role in entry or intra-
cellular survival of mycobacteria, we assessed cfu/ml in a fibro-
blast cell line derived from wild-type mice (3T3) or from mice
lacking both c-ABL1 and c-ABL2 (ABL1//ABL2/). Cfu of
Mm decreased by up to 3.6-fold at 72h p.i. in ABL1//ABL2/
cells compared to 3T3 cells, suggesting that ABL1 and ABL2 are
required for intracellular survival of Mm (Figure 2G). Because
neither 3T3 cells nor ABL1//ABL2/ cells were susceptible478 Cell Host & Microbe 10, 475–485, November 17, 2011 ª2011 Elsevier Inc.to infection with this bacterium, even at a high
multiplicity of infection (moi) (60), we were
unable to evaluate Mtb in ABL1//ABL2/
cells. Moreover, no differences between 3T3
cells and ABL1//ABL2/ cells at the initial
time points were evident with Mm infections.
Because these data raised the possibility that
entry mechanisms in fibroblasts differed from
macrophages, they were not evaluated further.
Treatment of ABL1//ABL2/ cells with im-
atinib reduced cfu/ml by an additional 3.5-fold
suggesting that cellular targets of imatinib other
than ABL family TKs also mediate intracellular
survival of mycobacteria. Stem cell differentia-
tion (c-KIT), macrophage differentiation and
function (M-CSF1R), cell growth alpha
(PDGFRa), and PDGFRb are also inhibited by
imatinib (Buchdunger et al., 2000; Carroll et al.,
1997; Dewar et al., 2005). However, we could
find no significant difference in the entry or intra-
cellular survival of Mm in PDGFRa/,
PDGFRb/ or PDGFRa/b/ cells or in the
presence of neutralizing antibodies to c-KIT orm-CSF1 compared to control cells (data not shown). Collec-
tively, these data suggest that ABL family TKs, together with
additional imatinib-sensitive factors, regulate intracellular traf-
ficking of Mm.
Imatinib Reduces Bacterial Load in Mice Infected
with Mycobacterium marinum
To determine whether ABL family TKs mediate intracellular
survival of mycobacteria in vivo, we assessed the effects of
imatinib onmice infectedwithMm. In accordancewith a previous
report, injection of 105 cfu Mm into the tail vein resulted in the
colonization of spleen, liver, and lung (Robinson et al., 2007).
Cfu/g of tissue (cfu/g) increased to maximal levels by 7 days
p.i., with the highest mean levels evident in spleen (6.9 3
105 cfu/g) compared to liver (9.4 3 104 cfu/g) and lung (1.5 3
104 cfu/g (Figures 3A–3C), controls).
Next, we assessed the effects of imatinib, administered at
doses ranging from 25 to 200 mg/kg/day, or the carrier (water),
Figure 4. Imatinib Reduces Liver Pathology and
Tail Lesions in Mice Infected with Mycobacterium
marinum
(A) H&E-stained sections of livers of mice left uninfected
and treated with 100 mg/kg/day imatinib, or infected and
treated with H2O or 100 mg/kg/day imatinib 1day prior
to infection. Arrows depict individual lesions. Magnifica-
tion 3100.
(B) Quantitation of the number of lesions present in liver
sections/mm2. Data were derived from 27 liver sections
from mice in three experiments. Data are presented as
mean +/ SEM; p values were determined by a Mann-
Whitney rank sum test.
(C) Acid fast (upper) or H&E (lower) staining of adjacent
sections of spleen taken from infected and untreated mice
from Figure 3A. Arrows indicateMm. Magnification 3400.
(D) Images of tails from mice infected intravenously with
107 cfu/ml Mm 1218R and treated with carrier (H2O) or
imatinib (100 mg/kg/day) for 7 days beginning 24 h p.i.
Each mouse received one injection. Images are repre-
sentative of three independent experiments.
(E) Effects of imatinib (100 mg/kg/day) on the extent of tail
lesions. Size of lesions on a particular tail were measured
and summed, and the values were depicted in cm. Data
are represented as the mean cumulative lesion size/tail
from 15 tails from each experimental group. +/ SD;
p values were determined by a Mann-Whitney rank sum
test.
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for the duration of the experiment. At concentrations of 50–
100 mg/kg/day, imatinib reduced the median cfu/gm by 13- to
64-fold (Figure 3A), a statistically significant effect. At lower
(25 mg/kg/day) or higher (200 mg/kg/day) concentrations, imati-
nib produced a somewhat smaller effect. Statistically significant
reductions in bacterial load by imatinib (100 mg/kg/day) were
also evident in liver and lung (Figures 3B and 3C). Additionally,
administration of imatinib (100 mg/kg/day) reduced bacterial
load when delivered beginning either 1h or 24 hr p.i. (Figures
3D and 3E).
Imatinib Reduces Liver Pathology and Tail Lesions
in Mice Infected with Mycobacterium marinum
Histological examination of infected liver indicated the presence
of granulomatous lesions that were characterized by monocytic
infiltrates seven days p.i., whereas no such lesions were evident
in uninfected controls (e.g., compare the upper and middle
panels in Figures 4A and 4B). These lesions resembled those
seen in livers of mice following intravenous injection with MtbCell Host & Microbe 10, 475–(Hu et al., 2000). Lesions were also evident in
spleen and were associated with mycobacteria
infiltrates, as assessed by acid-fast staining of
adjacent sections (e.g., Figure 4C), whereas
lesions in liver were not. However, because
the load in spleen was 10-fold higher than
liver, it remains possible that bacteria were
more readily observable in adjacent sections.
Administration of imatinib (100 mg/kg/day)
either before or after infection caused a 3.5-
fold decrease in the number of lesions/mm2 ofliver (e.g., Figures 4A and 4B). Inoculums of 107 cfuMm induced
lesions on the tail, beginning at the site of injection and extending
distally. These lesions were reduced in size and extent upon
administration of imatinib either prior to or after infection (e.g.,
Figures 4D and 4E). Collectively, these data indicate that imatinib
reduces not only bacterial load but also reduces the character-
istic pathology associated with mycobacterial infection.
Effects of Imatinib on Rifampicin-Resistant
Mycobacterium marinum
To determine whether imatinib was effective against antibiotic-
resistant mycobacteria, we generated a spontaneous rifam-
picin-resistant Mm mutant (MmR), which contained an H to Y
substitution at amino acid 134 in rpoB. This corresponds to the
H526Y substitution in Mtb rpoB, which causes high-level resis-
tance to rifamipicin in clinical isolates (Zhang, 2000). MmR did
not display a growth defect in the presence or absence of
1 mg/ml rifampicin in 7H9media compared to wild-typeMm (Fig-
ure 5A). In J774A.1 cells, imatinib caused a similar fold reduction
in the growth ofMmR and the parental strain (Figure 5B). In mice,485, November 17, 2011 ª2011 Elsevier Inc. 479
Figure 5. Imatinib Reduces Bacterial Load in Macrophages and
Mice Infected with Rifampicin-Resistant Mycobacterium marinum
(A) Growth curves of Mm, wild-type strain (Mm), or a rifampicin-resistant Mm
strain (MmR) in 7H9media left untreated or treated with 1 mg/ml rifampicin. Cell
density wasmeasured byOD600. Data in (A) and (B) are presented asmean +/
SEM.
(B) Intracellular survival of MmR (moi = 1) in J774A.1 macrophages in the
presence or absence of imatinib (10 mM).
(C) Effects of imatinib (100 mg/kg/day) on mice infected with 105 cfuMm strain
MmR. Cumulative data from three independent experiments are presented.
The line represents the median cfu; p values were calculated by a nonpara-
metric Mann-Whitney rank sum test.
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480 Cell Host & Microbe 10, 475–485, November 17, 2011 ª2011 Elsadministration of imatinib reduced the load ofMmR in the spleen
to a similar extent as that seen withMm (Figure 5C). These data
suggest that imatinib is effective against both antibiotic-suscep-
tible and antibiotic-resistant strains of Mm.
Imatinib and Antibiotics Synergistically Reduce
Bacterial Load
We next determined the effects of imatinib in conjunction with
first-line anti-TB drug drugs. J774A.1 cells were infected with
Mm and treated with imatinib, rifampicin, or a combination of
both. For these experiments, the rifampicin concentration
chosen only partially inhibited bacterial growth. As shown in
Figures 6A and 6B, the sum of the maximum fold reduction
with the combined treatment exceeded the sum of fold effects
with either drug alone, indicating a synergistic effect. Similar
effects were observed with Mtb, although the maximum fold
effect of rifampicin at the concentration used (0.125 mg/ml) was
larger than that forMm (Figure 6C). Together, these data suggest
that the combination of imatinib and rifampicin produced a syner-
gistic reduction in the survival of mycobacteria in macrophages.
We next assessed the effects of imatinib and antibiotics on
Mm infection in vivo. Rifampicin has been shown to induce levels
of cytochrome P450s that act directly on imatinib and reduce its
serum concentration in human plasma (Bolton et al., 2004). To
circumvent this problem, we used rifabutin, a much less-potent
inducer of cytochrome P450s (Reinach et al., 1999). As shown
in Figure 6D, imatinib and rifabutin together reduced median
cfu/ml to a level that exceeded the sum of either drug alone.
Similar effects were seen in liver (data not shown). Together,
these data suggest that imatinib acts in a synergistic manner
with first-line antibiotics when delivered in combination in vivo.
Imatinib Reduces Bacterial Load in Mice Infected
with Mycobacterium tuberculosis
We next determined whether imatinib affected intracellular
growth and survival of Mtb in vivo. We assessed the effects of
imatinib (66 or 100 mg/kg/day) or the carrier-control, beginning
24 hprior to infection and continuing for the duration of the exper-
iment. Mice were infected with a low dose (25–50 cfu) of aero-
solizedMtb (Erdman strain) and lungs were harvested to assess
the bacterial burden and disease pathology at 4weeks p.i. Signif-
icance was assessed by a Kruskal-Wallis nonparametric rank
sum test, wherein the data from the groups are pooled and
ranked according to cfu; the statistic determines whether the
observed distribution of rankings could arise by chance. As
shown in Figure 7A, imatinib reduced median cfu by 21- to
57-fold, a statistically significant effect (p = 0.035), though no
statistically significant difference was evident between the
groups treated with different doses of drug (p = 0.45). Taken
together, lung cfu were below the level of detection of plating
(10 cfu; dotted line in Figure 7A) in 56% of animals treated
with imatinib, with 78% below 105 cfu, compared to 20% below
the detection level and 80% greater than 105 cfu in the carrier-
treated group. Histopathological examination of the lungs from
a subset of mice, including those with cfu below the level of
detection, showed lymphocytic infiltrates (data not shown).
The observation that 20%of the carrier-treatedmice displayed
cfu below the level of detection was unusual led us to consider
the possibility that the osmotic pump interfered with theevier Inc.
Figure 6. Imatinib and Antibiotics Act in Synergy to
Reduce Mycobacteria Survival
(A) Intracellular survival of Mm (moi = 1) in J774A.1
macrophages left untreated or treated with imatinib
(10 mM), rifampicin (0.5 mg/ml), or both drugs together.
Cfu/ml were determined at times indicated.
(B) Maximal fold reduction in intracellular survival ofMm in
J774A.1 cells with various treatments compared to
controls at day 3 p.i.
(C) Maximal fold reduction in intracellular survival of Mtb
H37Rv in THP-1 cells (moi = 10) with imatinib (10 mM),
rifampicin (0.125 mg/ml), or both drugs together.
(D) Mice were administered imatinib (100 mg/kg/day),
rifabutin (2.5 mg/kg/day, intraperitoneally), or both drugs
together. Cfu in the spleen were determined at day 7 p.i.
Line represents the median. (n = 3; data from a represen-
tative experiment are presented). The line represents the
median cfu; p values were calculated by a nonparametric
Mann-Whitney rank sum test.
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nipulated (no pump and no drug) or carrier-treated mice were
exposed to aerosolized Mtb at a concentration of 2.5 3 105/ml
cfu or a higher concentration (1 3 107/ml cfu). As shown in Fig-
ure 7B, deposition ofMtb at 24 h p.i. was equivalent in the lungs
of unmanipulated mice compared to those with carrier pumps
for both concentrations of bacteria. Together, these data suggest
that the pumpswere without effect, but the reasons for the unde-
tectable cfu in carrier-treated animals in Figure 7A remain unclear.
To determine whether the undetectable cfu in carrier-treated
animals were an experimental anomaly, and also to confirm the
existence of a statistically significant difference in cfu between
the control and imatinib-treated groups, we carried out a second
28-day experiment in which we counted cfu from the entire lung
rather than a single lobe to avoid underestimating the number of
bacteria. We also included unmanipulated animals as controls.
As shown in Figure 7C, with a measured inoculum of approxi-
mately 50 cfu, there was no statistically significant difference
between unmanipulated mice (median cfu, 5.8 3 106) and
carrier-treated mice (median cfu, 6 3 106). Moreover, neither
group had outliers below the level of detection (10 cfu). Impor-
tantly, median cfu was reduced by 185-fold in the imatinib-Cell Host & Microbe 10, 475–treated group compared with the carrier-
controls, a statistically significant difference
(p = 0.001), with 30% of the animals displaying
cfu below the level of detection. Examination of
cfu from spleen followed a pattern similar to
lung, with median cfu reduced by 12-fold in
imatinib-treated animals compared to the
carrier-controls (Figure 7D). Moreover, animals
with cfu below detectable levels in lung likewise
had undetectable levels in spleen. Collectively,
these data suggest that imatinib is effective
againstMtb in acutely infected animals.
DISCUSSION
Using specific TKIs and cell lines derived from
knockout animals, we provide evidence fora role of host TKs, including ABL1, ABL2, and additional imati-
nib-sensitive kinases, in the entry and intracellular survival of
Mtb and related pathogenMm in macrophages. Pathogenic my-
cobacteria likely use multiple kinases in a redundant fashion,
perhaps as a means to infect cell types that express different
classes of kinases. TKs, including members of the ABL family,
are used by diverse bacterial and viral pathogens (reviewed in
[Lebeis and Kalman, 2009]). Notably, redundant usage of TKs
has been reported for several of these pathogens (Lebeis and
Kalman, 2009). A recent study showed that siRNA against the
ABL1 transcript appeared to facilitate survival of the Mtb strain
H37Rv in J774A.1 macrophages (Jayaswal et al., 2010).
However, experiments presented here using specific inhibitors,
as well as cells derived from knockout animals, suggest that
multiple kinases, including ABL1 and ABL2, mediate intracellular
survival within macrophages. The apparent disparity may be ex-
plained by redundant kinase usage, as suggested by our exper-
iments. A recent report indicated that nonspecific serine/threo-
nine kinase inhibitors affect MDR-Mtb growth in a primary
macrophage cell line, although it remains undetermined whether
these compounds affect additional targets in the bacteria or the
host, or both (Kuijl et al., 2007).485, November 17, 2011 ª2011 Elsevier Inc. 481
Figure 7. Imatinib Reduces Bacterial Load in Mice
Infected with Mycobacterium tuberculosis
(A) C57Bl/6 mice were infected with 50–100 cfu of aero-
solized Mtb Erdman. Beginning 24 h prior to infection,
animals were administered water (carrier) or imatinib at
concentrations of 66.7 mg/kg/day or 100 mg/kg/day. Cfu
was determined in right superior lobe of the lung at 28 days
p.i. Solid lines represent the median cfu; dotted line
represents the limit of detection (10 cfu); p values were
determined by a nonparametric Kruskal-Wallis test.
(B) C57Bl/6 mice were administered carrier pumps 24 h
prior to infection. Unmanipulated or carrier-treated mice
were infected with a low (2.5 3 105 cfu; left) or high dose
(1 3 107 cfu; right) of aerosolized Mtb Erdman and cfu
determined in the whole lung at 24 h p.i. The solid line
represents the median cfu.
(C and D) C57Bl/6 mice were infected with 2.53 105 cfu of
aerosolized Mtb Erdman. Beginning 24 h prior to infection,
animals were either left untreated or administered carrier
(water) or imatinib at a concentration of 66.7 mg/kg/day.
Cfu was determined by plating homogenates of the whole
lung (C) or spleen (D) at 28 days p.i. The solid line repre-
sents the median cfu; dotted line represents the limit of
detection (10 cfu); p values were determined by a
nonparametric Mann-Whitney test.
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ABL Family Kinases Regulate Mycobacterial InfectionOur data suggest that ABL or related TKs affect both entry of
mycobacteria into cells and intracellular survival. While a role for
ABL or related TKs in entry remains unexplored, several obser-
vations suggest a role for these TKs in vessicular trafficking. Im-
atinib causes the accumulation of acidified vesicles containing
LAMP-1 and LC3, which are markers for lysosomes and auto-
phagosomes, respectively (Ertmer et al., 2007; Yogalingam
and Pendergast, 2008), and the accumulation ofMm in the lyso-
some (Figure 2). Notably, stimulation of autophagy with rapamy-
cin or starvation reduces intracellular survival of mycobacteria in
macrophages (Gutierrez et al., 2004). Together, these data
suggest that imatinib-sensitive kinases mediate inhibition of
phagolysosomal fusion by mycobacteria.
Our data suggest that imatinib similarly affects Mtb, Ms, and
Mm in diverse cell types. Thus, imatinib-sensitive TKs may serve
as a node that mediates entry by multiple receptors or alters
receptor-mediated trafficking of a phagosome that is utilized
by several mycobacteria species. Mm is the closest genetic
relative to the Mtb complex based on 16S rRNA sequencing
and 85%Mm identity to orthologous regions of theMtb genome
(Stinear et al., 2008; Tønjum et al., 1998). Mm causes both
systemic and granulomatous disease in cold-blooded animals,
and also causes subcutaneous granulomas in humans due to
its preference for lower temperatures (Clark and Shepard,
1963). Notably, Mm exhibits a 5-fold faster generation time
compared to Mtb and requires only BSL2 containment, thereby
expediting data acquisition and optimization of drug dose and
delivery methodologies. The observation that Ms is similarly482 Cell Host & Microbe 10, 475–485, November 17, 2011 ª2011 Elsevier Inc.affected by imatinib suggests that the effects
of the drug are independent of the RD1 locus,
which is associated with virulence. This obser-
vation also raises the possibility that imatinib
might likewise be effective against other patho-genic mycobacteria, including M. avium, M. intracellulare,
M. ulcerans, and M. leprae.
Some differences exist between Mtb and Mm. Mm escapes
the phagosome, and our data and that of others indicate that
Mm forms actin tails after 48 h, facilitating infection of adjacent
cells (Stamm et al., 2003). Recent reports suggest that Mtb
also escapes the phagosome (van der Wel et al., 2007), although
no actin motility has been observed. Notably, the effects of ima-
tinib on infectivity ofMm in vitro are evident prior to 48 h, and no
reduction in actin tails was apparent when imatinib was applied
at 48 h or in cells lacking ABL family TKs (data not shown). Thus,
differences in actin motility betweenMtb andMm in vitro appear
independent of host TKs.
Imatinib may have significant utility in treating infections
caused by mycobacteria. Imatinib reduced cfu in organs of
mice infected with Mtb (Figure 7) or Mm (Figure 3). The effect
of imatinib on bacterial load was dose-dependent with optimal
concentrations of 66.7–100 mg/kg/day, the approximate dose
used to treat CML in humans (Goldman and Druker, 2001).
Although clearance of Mtb to levels below the limit of detection
was evident in some animals (Figures 7A, 7C, and 7D), clearance
was not observed in Mm experiments, perhaps owing to the
shorter time-course, higher inoculum (105 cfu for Mm versus
50 cfu for Mtb), or the route of inoculation. For reasons that
are unclear, considerable variance was evident in cfu for both
Mtb andMm infections with imatinib administration, even within
a single experiment, although median cfu were consistently
lower (Figures 3 and 7). Other disease indicators in animals
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ABL Family Kinases Regulate Mycobacterial Infectioninfected with Mm, including lymphocytic or monocytic aggre-
gates in the liver and superficial lesions on the tail, were reduced
upon treatment with imatinib (Figure 4).
Based on in vitro studies, reductions in cfumay reflect a reduc-
tion in the number of bacteria entering macrophages or their
intracellular survival, or both. We also show that imatinib and
the first-line antibiotic, rifampicin, when provided together, can
act in a synergistic fashion to reduce survival of Mtb and Mm in
macrophages (Figures 6A and 6B and data not shown); imatinib
and rifabutin act similarly in vivo. It remains possible that in vivo
treatment with imatinib results in an increased number of extra-
cellular bacteria, whichmaybe exposed to higher concentrations
of antibiotics. Alternatively, localization of intracellular bacteria in
a lysosomal compartment, which occurs upon treatmentwith im-
atinib, may render them more susceptible to antibiotics.
Besides ABL family TKs, imatinib inhibits receptor TKs respon-
sible for mast cell development, c-KIT, m-CSF1R, and PDGFR
(Buchdunger et al., 2000; Carroll et al., 1997; Dewar et al.,
2005). Thus, we cannot rule out the possibility that additional
immunomodulatory effects contribute to the observed pheno-
type. In this regard, imatinib appeared more efficacious at lower
concentrations (Figure 3A), suggesting that the drug may exert
concentration-dependent effects on factors important for
control of the infection.
When considering drugs directed at host targets, toxicity
toward the host remains a primary concern. Thus, host mole-
cules that are essential for survival or are required to mount an
effective immune response may prove difficult to target. Imatinib
has exhibited remarkably low toxicity in patients, though some
recent reports indicate side effects on the heart and the immune
system with long-term exposure (Kerkela¨ et al., 2006; Mum-
precht et al., 2006). Adjusting the dosing regimen or limiting
the period of exposure may mitigate such effects. Imatinib may
prove most effective in patients when the bacteria are actively
growing (active TB) or with reactivated TB, which may warrant
acute, rather than sustained, exposure to the drug. We have
not pursued in vivo studies with dual ABL and SRC family
TKIs, such as Sprycel (BMS-354825) or PD-166326, because
these drugs cause significant immunotoxicity (EMEA, 2008),
which has proven insurmountable in an orthopoxvirus infection
model (Reeves et al., 2011).
Here, we provide evidence that host TKs, including ABL1,
ABL2, and other imatinib-sensitive kinases, regulate the patho-
genesis of Mtb and Mm in vitro and in vivo. Data from macro-
phages and mice indicate that infections caused by Mm and
Mtb are similarly sensitive to imatinib. Similar imatinib-sensitive
kinases may govern trafficking ofMm andMtb in macrophages.
In vivo, however, the mechanism by which imatinib reducesMtb
cfu may be more complex than with Mm. In the Mm model,
effects of imatinib are evident within 3–7 days and cfu reductions
likely reflect entry or intracellular trafficking of bacterium or
innate immune effects. Such effects may also be important in
Mtb infections, but at 28 days adaptive responses may also
contribute. We are currently investigating how imatinib impacts
the innate and adaptive responses in animals infected with
Mycobacteria sp. Nevertheless, because of its relatively rapid
growth rate and limited biocontainment requirements, Mm may
be useful for initial phases of drug discovery for acute mycobac-
teria infections in vitro and in vivo.Cell Host &Additionally, our data suggest that imatinib may prove useful
against both antibiotic-susceptible and antibiotic-resistant
strains of Mtb, including MDR-TB and XDR-TB (e.g., Figure 5).
Because imatinib targets host TKs, not bacterial factors, it is
less likely to engender resistance compared to conventional
antibiotics. To evade the block and develop resistance, Mtb
would have to significantly alter its pathogenic strategy. More-
over, when delivered in conjunction with current first-line anti-
TB drugs, decreasing the total bacterial burden below the spon-
taneous mutation frequency with imatinib may serve to reduce
the probability of developing antibiotic-resistant disease,
thereby increasing the clinical lifespan of those drugs.
EXPERIMENTAL PROCEDURES
Cell Culture
Fibroblast cell lines derived fromwild-typemice or ABL1/ABL2/mice (55)
and the mouse macrophage cell line J774A.1 were maintained in Dulbecco’s
modified Eagle’s medium (DMEM). Human type II alveolar pneumocyte cell
(A549) were grown in Eagle’s minimal essential medium, and human mono-
cytic-like cells (THP-1) were grown in RPMI1640. Media was supplemented
with 10% fetal bovine serum (FBS) and 2 mM L-glutamine. For some experi-
ments, THP-1 cells were differentiated by adding 10 ng/ml Phorbol 12-myris-
tate 13-acetate (PMA) (Sigma), and J774A.1 cells were activatedwith 100 U/ml
INF-g (BD Biosciences PharMingen, San Diego, CA).
Bacterial Strains, Growth Conditions, and Mutants
Mtb strain H37Rv (TMC102) andMm strain 1218R (ATCC 927), a fish outbreak
isolate, were grown in Middlebrook 7H9 broth (7H9) (BBL Microbiology
Systems, Cockeysville, MD) supplemented with ADC (Difco Laboratories, De-
troit, MI) and 0.05% Tween 80 (Mtb) (Sigma, St. Louis, MI) or 0.025% Tween
80 (Mm). Middlebrook 7H11 agar was used for Mtb, and Middlebrook 7H10
agar for Mm. Both were supplemented with 10% oleic acid-albumin-
dextrose-catalase (OADC; Difco Laboratories, Sparks, MD). Mtb stocks
were grown at 37C in 5% CO2 and shaken at 70 rpm for 7 days to an optical
density of 0.6 (OD600), as measured by a Novaspec II spectrophotometer
(AmershamPharmacia Biotech, Uppsala, Sweden). Cells were pelleted, resus-
pended in fresh 7H9 broth, aliquoted, and stored at 70C. After freezing, an
aliquot was thawed for viable count assays on 7H11 agar. Mm stocks were
grown at 30C for 3 days to an OD600 of 0.8, and the cells pelleted, resus-
pended in fresh 7H9 broth, aliquoted, and stored at 80C. After freezing,
an aliquot was thawed to perform viable count assays on 7H10 agar supple-
mented with OADC. To generate rifampicin-resistant Mm mutants, strain
1218R was grown on 7H10 agar plates with 1 mg rifampicin/ml (Sigma) for
7 days. Colonies were restreaked to confirm resistance, and mutants were as-
sessed in growth curves. The mutation was identified by amplifying and then
sequencing the rifampicin resistance-determining region of rpoB using
primers 50GACGACATCGACCACTTC30 and 30TAGTCCACCTCTGACGAG50.
In Vitro Mycobacterium tuberculosis Infections
THP-1 cells were seeded at 106 cells/well in a 24-well microculture plate and
differentiated with PMA. After 48 h, the cells were washed once and fresh
RPMI media was added. A549 cells or J774A.1 were seeded at 3 3
105 cells/well in 24-well plates and incubated for 48 h prior to infection. For
infections, frozen Mtb stocks were thawed and centrifuged, the supernatant
was removed, and the pellet was resuspended in media without antibiotics.
Bacteria were centrifuged again, resuspended in fresh medium, washed twice
with 20 ml of medium, transferred to a 50 ml Oakridge tube containing 30
3mmglass beads, and vortexed for 15 s to disperse clumps and obtain a single
cell suspension.
Mammalian cells infected in triplicate with Mtb (moi = 10) for 2 h in RPMI
without FBS, after which extracellular Mtb were killed by adding 200 mg/ml
amikacin (Sigma) and incubating them at 37C with 5% CO2 for an additional
2 h. Monolayers were washed 5 times with RPMI and the cultures were incu-
bated at 37Cwith 5%CO2. At 24 h intervals, supernatants were removed and
the monolayers were lysed in 0.1% Triton X-100 (Sigma) for 15 min. Three setsMicrobe 10, 475–485, November 17, 2011 ª2011 Elsevier Inc. 483
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Tween 80 (Sigma), and portions were plated on 7H11 agar. Colonies were
counted after incubation (3–4 weeks) at 37C in 5% CO2.
In Vitro Mycobacterium marinum Infections
J774A.1, ABL1//ABL2/, or 3T3 cells were plated at 105 cells/ml in 24-well
plates and allowed to adhere overnight. A frozen vial of 1218R Mm was
thawed, the sample was centrifuged, and the pellet was resuspended in
DMEM with 10% FBS and then used to inoculate fresh media at 105 cfu/ml.
One ml of the Mm-containing DMEM/FBS was added to each well (moi = 1)
and the plates were incubated at 30C with 5% CO2 for 2 h, rinsed twice
with fresh PBS, and incubated with 200 mg/ml amikacin for an additional 2 h
to kill remaining extracellular Mm. Cells were then washed twice with PBS
and the media was replaced with DMEM/FBS. At 4 h p.i. (time 0) and at 5,
10, 15, 20, 25, or 48 h thereafter, the supernatant was removed and the mono-
layers were lysed in 0.1% Triton X-100 (Sigma) for 10 min. Three sets of serial
10-fold dilutions of the lysates from each well were plated on 7H10 agar and
colonies were counted after 7 days incubation at 30C. Data presented are
from at least three independent experiments.
Determination of Mycobacterium marinum Entry
After 4 h, the percentage of infected J774A.1 cells was measured using aMm
strain constitutively expressing plasmid-encoded GFP under the control of the
secA promoter. Infected cells were distinguished by live imaging with a scien-
tific-grade, cooled charge-coupled device (Cool-Snap HQ with ORCA-ER
chip) on a multiwavelength, wide-field, 3D microscopy system (Intelligent
Imaging Innovations, Denver, CO), based on a Zeiss 200M inverted micro-
scope using a 633 lens with a numerical aperture of 1.4 (Carl Zeiss, Thorn-
wood, NY). To measure cfu with imatinib present, J774A.1 cells were plated
at 105/well for one day and then chilled to 4C for 20 min prior to the addition
of bacteria and drug. To synchronize entry, Mm (moi = 1) was added at 4C,
and the bacteria and cells were centrifuged at 700 g for 10 min at 4C. The
culture dish was then returned to 37C for 15, 30, 60, or 120 min. At each
time point, cells were washed twice with PBS and incubated for an additional
2 h with media containing 200 mg/ml amikacin. Monolayers were washed twice
with PBS and lysed with 0.1% Triton X-100. Cfu/ml was determined as above.
Uptake percentage was measured by dividing the number of internalized
bacteria by the cfu/ml of the inoculum.
Measurement of Mycobacterium marinum in Lysosomes
To determine intracellular localization, J774A.1 cells were plated in 8-well
Lab-Tek chambered coverglass plates at 105 cells/well (Nunc, Nalge Nunc
International), infected with GFP-Mm (moi 1) for 2 h, and then treated with
200 mg/ml Amikacin for an additional 2 h. Cells were washed and media, alone
or supplemented with imatinib, was added. The cells were then incubated at
30C. After 24 h, 50 nM of lysotracker red (Invitrogen) was added and cells
were imaged as described above. The GFP fluorescence that colocalized
with lysotracker red was quantified.
In Vivo Mycobacterium tuberculosis Infections
Age-matched unmanipulated mice, carrier controls containing water pumps,
or mice containing pumps with imatinib were infected with Mtb Erdman
(Trudeau Institute, Saranac, NY) of Mtb using a nose-only aerosolization
system (In-Tox Products, Albuquerque, NM). Mice were exposed for 20 min
to a nebulized suspension of bacteria at a density 2.5 3 105/ml cfu or 1 3
107/ml cfu that was optimized to deliver a dose of approximately 25 or
200 cfu to the lungs. Mice were sacrificed 1 day or 28 days p.i. The whole
lung or right superior lobe of the lung was homogenized in PBS containing
0.05% Tween-80, and serial dilutions were plated onto 7H11 agar. The plates
were incubated at 37C and colonies were counted after 3 weeks.
In Vivo Mycobacterium marinum Infections
Six-week old male C57Bl/6 mice were injected in the tail vein with active
growing cultures at 105 cfu/mouse. The number of bacteria injected for
each experiment was determined by retrospective plating. The average
dose was 2.5 3 105 cfu/mouse. For experiments to determine the effects of
drugs on tail lesions, mice were infected at 107 cfu/ml. Seven days after infec-
tion, lung, liver, and spleen were harvested, weighed, and homogenized484 Cell Host & Microbe 10, 475–485, November 17, 2011 ª2011 Els(Fisher Scientific, Tissuemiser) in 1 ml PBS. Each homogenate was diluted
and spread on 7H10 agar. Colonies were scored after 7 days of incubation
at 30C. Total weight of the organ and colonies/ml of the homogenized organ
were used to determine cfu/g. For histology studies, the liver was removed,
fixed in 10% formalin, and embedded in paraffin. Sections were cut, stained
with hematoxylin and eosin (H&E) or Ziehl-Neelsen (acid-fast bacillus), and
imaged on a Nikon Eclipse 80i microscope.
Delivery of Drugs In Vivo
For experiments with imatinib, the mesylate salt was dissolved in water and
loaded into Alzet pumps (Braintree Scientific, 1007D) capable of dispensing
a continuous flow of drug at 25, 50, 100, or 200 mg/kg/day. Pumps were in-
serted subcutaneously into anesthetized 6-week-old male C57Bl/6 mice
(Jackson Laboratories). At these doses, we observed no weight loss or other
adverse effects in uninfected animals. Moreover, such doses have been
used to treat cancer in mice and are equivalent to those used in humans,
with adjustments for differences in pharmacodynamics and pharmacokinetics
(Wolff and Ilaria, 2001). For pretreatment experiments, water or imatinib-con-
taining pumps were inserted 24 h prior toMtb Erdman or intravenous injection
ofMm 1218R or rifampicin-resistantMm 1218R (MmR), and delivery wasmain-
tained for the duration of the experiment. For same day and aerosol inoculation
of posttreatment experiments, mice were infected withMm for either 1 or 24 h,
respectively, before inserting the pump. For both pre- and posttreatment
experiments, the mice were euthanized on day 7 for Mm or day 28 for Mtb.
Cfu was measured as described above. For synergy experiments, mice
were injected intraperitoneally with 2.5 mg/kg rifabutin (sigma) solubilized in
100% DMSO once a day for 7 days.
Statistical Analysis
Statistical analysis was done using nonparametric tests including the Mann-
Whitney rank sum test, the Wilcoxan rank sum test, or the Kruskal-Wallis
test. All of these tests pool the data and rank the values. The statistic calculates
the probability that the observed ranking occurred by chance. Values less than
or equal to 0.05 were considered statistically significant.
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